ABVC

Investor Moves

Name	Value	Action	Change	Price	Current Price
Jim SimonsRenaissance Technologies $92k95.1k shares TrimQ1 2026 $151k $1.65 $1.39
Ken GriffinCitadel Advisors $-118.3K ExitQ1 2026 $118k $1.65 $1.39
Jim SimonsRenaissance Technologies $243k114.3k shares TrimQ4 2025 $93k $2.68 $1.39
Ken GriffinCitadel Advisors $118k55.5k shares AddQ4 2025 $71k $2.68 $1.39
Jim SimonsRenaissance Technologies $243.1K AddQ3 2025 $243k $3.07 $1.39
Ken GriffinCitadel Advisors $-24.0K ExitQ1 2025 $24k $0.6071 $1.39

News

defenseworld.netContrasting ABVC BioPharma (NASDAQ:ABVC) and Edgewise Therapeutics (NASDAQ:EWTX)defenseworld.netApr 27

defenseworld.netABVC BioPharma (NASDAQ:ABVC) Stock Price Down 3.4% – Time to Sell?defenseworld.netApr 24

defenseworld.netABVC BioPharma (NASDAQ:ABVC) Trading Up 11.3% – Here’s Whydefenseworld.netApr 2

Trade ABVC

About ABVC BioPharma, Inc.

ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating novel drugs and medical devices to address critical, underserved healthcare requirements across the United States. The company's pipeline includes several key candidates: ABV-1501, currently undergoing Phase I/II clinical trials, is being developed as a combination treatment for triple-negative breast cancer. ABV-1504 has successfully completed Phase II clinical trials for major depressive disorders. ABV-1505 is progressing through Phase II clinical studies for attention deficit hyperactivity disorder (ADHD). ABV-1703 has concluded its Phase I clinical trials for the treatment of pancreatic cancer. ABV-1702 has also finished Phase I clinical investigations for myelodysplastic syndromes. ABV-1601 is in Phase I/II clinical trials, aimed at alleviating depression in individuals with cancer. ABV-1701 Vitargus is in development to treat conditions such as retinal detachment or vitreous hemorrhage. ABVC BioPharma maintains strategic alliances, including a co-development arrangement with Rgene Corporation, alongside collaborative agreements with BioHopeKing Corporation and BioFirst Corporation. The company's headquarters are located in Fremont, California, and it operates as a subsidiary of YuanGene Corporation.

CEO: Uttam Yashwant Patil
IPO Date: Nov 10, 2004

Market Data

Open: $1.37
High: $1.41
Low: $1.30
Volume: 57.5K
Avg Volume: 118K
52W High: $5.48
52W Low: $0.88

Valuation

Market Cap: $20M
Enterprise Value: $22M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-3.0M
Revenue: $0
Net Income: $-7.9M
Cash: $681k
Debt: $3.5M

Events

EarningsMay 19

EPS est. -0.4